{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,17]],"date-time":"2026-09-17T12:31:47Z","timestamp":1789648307752,"version":"4.0.0"},"reference-count":50,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2018,9,17]],"date-time":"2018-09-17T00:00:00Z","timestamp":1537142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Sci Rep"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Pediatric high-grade brain tumors and adult glioblastoma are associated with significant morbidity and mortality. Oncolytic herpes simplex virus-1 (oHSV) is a promising approach to target brain tumors; oHSV G207 and M032 (encodes human interleukin-12) are currently in phase I clinical trials in children with malignant supratentorial brain tumors and adults with glioblastoma, respectively. We sought to compare the sensitivity of patient-derived pediatric malignant brain tumor and adult glioblastoma xenografts to these clinically-relevant oHSV. In so doing we found that pediatric brain tumors were more sensitive to the viruses and expressed significantly more nectin-1 (CD111) than adult glioblastoma. Pediatric embryonal and glial tumors were 74-fold and 14-fold more sensitive to M002 and 16-fold and 6-fold more sensitive to G207 than adult glioblastoma, respectively. Of note, pediatric embryonal tumors were more sensitive than glial tumors. Differences in sensitivity may be due in part to nectin-1 expression, which predicted responses to the viruses. Treatment with oHSV resulted in prolonged survival in both pediatric and adult intracranial patient-dervied tumor xenograft models. Our results suggest that pediatric brain tumors are ideal targets for oHSV and that brain tumor expression of nectin-1 may be a useful biomarker to predict patient response to oHSV.<\/jats:p>","DOI":"10.1038\/s41598-018-32353-x","type":"journal-article","created":{"date-parts":[[2018,9,11]],"date-time":"2018-09-11T16:21:24Z","timestamp":1536682884000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":73,"title":["Enhanced Sensitivity of Patient-Derived Pediatric High-Grade Brain Tumor Xenografts to Oncolytic HSV-1 Virotherapy Correlates with Nectin-1 Expression"],"prefix":"10.1038","volume":"8","author":[{"given":"Gregory K.","family":"Friedman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-7814-3867","authenticated-orcid":false,"given":"Joshua D.","family":"Bernstock","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dongquan","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Nan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Blake P.","family":"Moore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Virginia M.","family":"Kelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Samantha L.","family":"Youngblood","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Catherine P.","family":"Langford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiaosi","family":"Han","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric K.","family":"Ring","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elizabeth A.","family":"Beierle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G. Yancey","family":"Gillespie","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James M.","family":"Markert","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2018,9,17]]},"reference":[{"issue":"Suppl 10","key":"32353_CR1","doi-asserted-by":"publisher","first-page":"x1","DOI":"10.1093\/neuonc\/nou327","volume":"16","author":"QT Ostrom","year":"2015","unstructured":"Ostrom, Q. T. et al. Alex\u2019s Lemonade Stand Foundation Infant and Childhood Primary Brain and Central Nervous System Tumors Diagnosed in the United States in 2007\u20132011. Neuro Oncol 16(Suppl 10), x1\u2013x36, https:\/\/doi.org\/10.1093\/neuonc\/nou327 (2015).","journal-title":"Neuro Oncol"},{"key":"32353_CR2","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1093\/neuonc\/nox158","volume":"19","author":"QT Ostrom","year":"2017","unstructured":"Ostrom, Q. T. et al. CBTRUS Statistical Report: Primary brain and other central nervous system tumors diagnosed in the United States in 2010\u20132014. Neuro Oncol 19, v1\u2013v88, https:\/\/doi.org\/10.1093\/neuonc\/nox158 (2017).","journal-title":"Neuro Oncol"},{"key":"32353_CR3","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1016\/S1470-2045(09)70025-7","volume":"10","author":"R Stupp","year":"2009","unstructured":"Stupp, R. et al. Effects of radiotherapy with concomitant and adjuvant temozolomide versus radiotherapy alone on survival in glioblastoma in a randomised phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet Oncol 10, 459\u2013466, https:\/\/doi.org\/10.1016\/S1470-2045(09)70025-7 (2009).","journal-title":"Lancet Oncol"},{"key":"32353_CR4","doi-asserted-by":"publisher","first-page":"2339","DOI":"10.1200\/JCO.2008.21.1953","volume":"27","author":"L Diller","year":"2009","unstructured":"Diller, L. et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol 27, 2339\u20132355, https:\/\/doi.org\/10.1200\/JCO.2008.21.1953 (2009).","journal-title":"J Clin Oncol"},{"key":"32353_CR5","doi-asserted-by":"publisher","first-page":"2780","DOI":"10.1200\/JCO.2014.58.3377","volume":"33","author":"RH Andtbacka","year":"2015","unstructured":"Andtbacka, R. H. et al. Talimogene Laherparepvec Improves Durable Response Rate in Patients With Advanced Melanoma. J Clin Oncol 33, 2780\u20132788, https:\/\/doi.org\/10.1200\/JCO.2014.58.3377 (2015).","journal-title":"J Clin Oncol"},{"key":"32353_CR6","doi-asserted-by":"publisher","first-page":"843","DOI":"10.1073\/pnas.94.3.843","volume":"94","author":"B He","year":"1997","unstructured":"He, B., Gross, M. & Roizman, B. The gamma(1)34.5 protein of herpes simplex virus 1 complexes with protein phosphatase 1alpha to dephosphorylate the alpha subunit of the eukaryotic translation initiation factor 2 and preclude the shutoff of protein synthesis by double-stranded RNA-activated protein kinase. Proceedings of the National Academy of Sciences of the United States of America 94, 843\u2013848 (1997).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"32353_CR7","doi-asserted-by":"publisher","first-page":"745","DOI":"10.1038\/35087061","volume":"3","author":"F Farassati","year":"2001","unstructured":"Farassati, F., Yang, A. D. & Lee, P. W. Oncogenes in Ras signalling pathway dictate host-cell permissiveness to herpes simplex virus 1. Nature cell biology 3, 745\u2013750, https:\/\/doi.org\/10.1038\/35087061 (2001).","journal-title":"Nature cell biology"},{"key":"32353_CR8","doi-asserted-by":"publisher","first-page":"1110","DOI":"10.1128\/JVI.80.3.1110-1120.2006","volume":"80","author":"KD Smith","year":"2006","unstructured":"Smith, K. D. et al. Activated MEK suppresses activation of PKR and enables efficient replication and in vivo oncolysis by Deltagamma(1)34.5 mutants of herpes simplex virus 1. Journal of virology 80, 1110\u20131120, https:\/\/doi.org\/10.1128\/JVI.80.3.1110-1120.2006 (2006).","journal-title":"Journal of virology"},{"key":"32353_CR9","doi-asserted-by":"publisher","first-page":"292","DOI":"10.1038\/sj.gt.3301885","volume":"10","author":"BL Liu","year":"2003","unstructured":"Liu, B. L. et al. ICP34.5 deleted herpes simplex virus with enhanced oncolytic, immune stimulating, and anti-tumour properties. Gene Ther 10, 292\u2013303, https:\/\/doi.org\/10.1038\/sj.gt.3301885 (2003).","journal-title":"Gene Ther"},{"key":"32353_CR10","doi-asserted-by":"publisher","first-page":"7","DOI":"10.1089\/humc.2017.002","volume":"28","author":"AM Waters","year":"2017","unstructured":"Waters, A. M. et al. Rationale and Design of a Phase 1 Clinical Trial to Evaluate HSV G207 Alone or with a Single Radiation Dose in Children with Progressive or Recurrent Malignant Supratentorial Brain Tumors. Hum Gene Ther Clin Dev 28, 7\u201316, https:\/\/doi.org\/10.1089\/humc.2017.002 (2017).","journal-title":"Hum Gene Ther Clin Dev"},{"key":"32353_CR11","doi-asserted-by":"publisher","first-page":"69","DOI":"10.1089\/humc.2016.031","volume":"27","author":"DM Patel","year":"2016","unstructured":"Patel, D. M. et al. Design of a Phase I Clinical Trial to Evaluate M032, a Genetically Engineered HSV-1 Expressing IL-12, in Patients with Recurrent\/Progressive Glioblastoma Multiforme, Anaplastic Astrocytoma, or Gliosarcoma. Hum Gene Ther Clin Dev 27, 69\u201378, https:\/\/doi.org\/10.1089\/humc.2016.031 (2016).","journal-title":"Hum Gene Ther Clin Dev"},{"key":"32353_CR12","doi-asserted-by":"publisher","first-page":"867","DOI":"10.1038\/sj.gt.3301205","volume":"7","author":"JM Markert","year":"2000","unstructured":"Markert, J. M. et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a phase I trial. Gene Ther 7, 867\u2013874, https:\/\/doi.org\/10.1038\/sj.gt.3301205 (2000).","journal-title":"Gene Ther"},{"key":"32353_CR13","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1038\/mt.2008.228","volume":"17","author":"JM Markert","year":"2009","unstructured":"Markert, J. M. et al. Phase Ib trial of mutant herpes simplex virus G207 inoculated pre-and post-tumor resection for recurrent GBM. Molecular therapy: the journal of the American Society of Gene Therapy 17, 199\u2013207, https:\/\/doi.org\/10.1038\/mt.2008.228 (2009).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"32353_CR14","doi-asserted-by":"publisher","first-page":"1048","DOI":"10.1038\/mt.2014.22","volume":"22","author":"JM Markert","year":"2014","unstructured":"Markert, J. M. et al. A phase 1 trial of oncolytic HSV-1, G207, given in combination with radiation for recurrent GBM demonstrates safety and radiographic responses. Molecular therapy: the journal of the American Society of Gene Therapy 22, 1048\u20131055, https:\/\/doi.org\/10.1038\/mt.2014.22 (2014).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"32353_CR15","doi-asserted-by":"publisher","first-page":"286","DOI":"10.1016\/j.virol.2004.02.005","volume":"322","author":"C Krummenacher","year":"2004","unstructured":"Krummenacher, C. et al. Comparative usage of herpesvirus entry mediator A and nectin-1 by laboratory strains and clinical isolates of herpes simplex virus. Virology 322, 286\u2013299, https:\/\/doi.org\/10.1016\/j.virol.2004.02.005 (2004).","journal-title":"Virology"},{"key":"32353_CR16","doi-asserted-by":"publisher","first-page":"938","DOI":"10.1038\/nm0995-938","volume":"1","author":"T Mineta","year":"1995","unstructured":"Mineta, T., Rabkin, S. D., Yazaki, T., Hunter, W. D. & Martuza, R. L. Attenuated multi-mutated herpes simplex virus-1 for the treatment of malignant gliomas. Nature medicine 1, 938\u2013943 (1995).","journal-title":"Nature medicine"},{"key":"32353_CR17","doi-asserted-by":"publisher","first-page":"2208","DOI":"10.1073\/pnas.040557897","volume":"97","author":"JN Parker","year":"2000","unstructured":"Parker, J. N. et al. Engineered herpes simplex virus expressing IL-12 in the treatment of experimental murine brain tumors. Proceedings of the National Academy of Sciences of the United States of America 97, 2208\u20132213, https:\/\/doi.org\/10.1073\/pnas.040557897 (2000).","journal-title":"Proceedings of the National Academy of Sciences of the United States of America"},{"key":"32353_CR18","doi-asserted-by":"crossref","unstructured":"Montgomery, R. I., Warner, M. S., Lum, B. J. & Spear, P. G. Herpes simplex virus-1 entry into cells mediated by a novel member of the TNF\/NGF receptor family. Cell 87, 427\u2013436, doi:S0092-8674(00)81363-X (1996).","DOI":"10.1016\/S0092-8674(00)81363-X"},{"key":"32353_CR19","doi-asserted-by":"publisher","first-page":"1267","DOI":"10.1128\/JVI.74.3.1267-1274.2000","volume":"74","author":"M Lopez","year":"2000","unstructured":"Lopez, M. et al. Nectin2alpha (PRR2alpha or HveB) and nectin2delta are low-efficiency mediators for entry of herpes simplex virus mutants carrying the Leu25Pro substitution in glycoprotein D. J Virol 74, 1267\u20131274 (2000).","journal-title":"J Virol"},{"key":"32353_CR20","doi-asserted-by":"publisher","first-page":"e82696","DOI":"10.1371\/journal.pone.0082696","volume":"8","author":"TA Martin","year":"2013","unstructured":"Martin, T. A., Lane, J., Harrison, G. M. & Jiang, W. G. The expression of the Nectin complex in human breast cancer and the role of Nectin-3 in the control of tight junctions during metastasis. Plos One 8, e82696, https:\/\/doi.org\/10.1371\/journal.pone.0082696 (2013).","journal-title":"Plos One"},{"key":"32353_CR21","doi-asserted-by":"publisher","first-page":"4889","DOI":"10.1158\/1078-0432.CCR-05-0309","volume":"11","author":"Z Yu","year":"2005","unstructured":"Yu, Z. et al. Enhanced nectin-1 expression and herpes oncolytic sensitivity in highly migratory and invasive carcinoma. Clin Cancer Res 11, 4889\u20134897, https:\/\/doi.org\/10.1158\/1078-0432.CCR-05-0309 (2005).","journal-title":"Clin Cancer Res"},{"key":"32353_CR22","doi-asserted-by":"crossref","first-page":"7064","DOI":"10.1128\/JVI.72.9.7064-7074.1998","volume":"72","author":"C Krummenacher","year":"1998","unstructured":"Krummenacher, C. et al. Herpes simplex virus glycoprotein D can bind to poliovirus receptor-related protein 1 or herpesvirus entry mediator, two structurally unrelated mediators of virus entry. Journal of virology 72, 7064\u20137074 (1998).","journal-title":"Journal of virology"},{"key":"32353_CR23","doi-asserted-by":"publisher","first-page":"200","DOI":"10.1593\/tlo.12115","volume":"5","author":"GK Friedman","year":"2012","unstructured":"Friedman, G. K. et al. Hypoxia Moderates gamma(1)34.5-Deleted Herpes Simplex Virus Oncolytic Activity in Human Glioma Xenoline Primary Cultures. Transl Oncol 5, 200\u2013207 (2012).","journal-title":"Transl Oncol"},{"key":"32353_CR24","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1016\/j.virol.2007.11.012","volume":"373","author":"KM Stiles","year":"2008","unstructured":"Stiles, K. M., Milne, R. S., Cohen, G. H., Eisenberg, R. J. & Krummenacher, C. The herpes simplex virus receptor nectin-1 is down-regulated after trans-interaction with glycoprotein D. Virology 373, 98\u2013111, https:\/\/doi.org\/10.1016\/j.virol.2007.11.012 (2008).","journal-title":"Virology"},{"key":"32353_CR25","doi-asserted-by":"publisher","first-page":"199","DOI":"10.1007\/s11060-009-9926-0","volume":"95","author":"GK Friedman","year":"2009","unstructured":"Friedman, G. K. et al. Engineered herpes simplex viruses efficiently infect and kill CD133+ human glioma xenograft cells that express CD111. Journal of neuro-oncology 95, 199\u2013209, https:\/\/doi.org\/10.1007\/s11060-009-9926-0 (2009).","journal-title":"Journal of neuro-oncology"},{"key":"32353_CR26","doi-asserted-by":"publisher","first-page":"103","DOI":"10.1038\/sj.mt.6300009","volume":"15","author":"Z Yu","year":"2007","unstructured":"Yu, Z. et al. Nectin-1 expression by squamous cell carcinoma is a predictor of herpes oncolytic sensitivity. Molecular therapy: the journal of the American Society of Gene Therapy 15, 103\u2013113, https:\/\/doi.org\/10.1038\/sj.mt.6300009 (2007).","journal-title":"Molecular therapy: the journal of the American Society of Gene Therapy"},{"key":"32353_CR27","doi-asserted-by":"publisher","first-page":"1965","DOI":"10.1210\/jc.2007-0040","volume":"92","author":"YY Huang","year":"2007","unstructured":"Huang, Y. Y. et al. Nectin-1 is a marker of thyroid cancer sensitivity to herpes oncolytic therapy. J Clin Endocrinol Metab 92, 1965\u20131970, https:\/\/doi.org\/10.1210\/jc.2007-0040 (2007).","journal-title":"J Clin Endocrinol Metab"},{"key":"32353_CR28","doi-asserted-by":"publisher","first-page":"761","DOI":"10.1038\/gt.2012.93","volume":"20","author":"PY Wang","year":"2013","unstructured":"Wang, P. Y. et al. Expression of HSV-1 receptors in EBV-associated lymphoproliferative disease determines susceptibility to oncolytic HSV. Gene Ther 20, 761\u2013769, https:\/\/doi.org\/10.1038\/gt.2012.93 (2013).","journal-title":"Gene Ther"},{"key":"32353_CR29","doi-asserted-by":"publisher","first-page":"419","DOI":"10.1016\/j.tranon.2016.07.008","volume":"9","author":"AM Waters","year":"2016","unstructured":"Waters, A. M. et al. Effect of Repeat Dosing of Engineered Oncolytic Herpes Simplex Virus on Preclinical Models of Rhabdomyosarcoma. Transl Oncol 9, 419\u2013430, https:\/\/doi.org\/10.1016\/j.tranon.2016.07.008 (2016).","journal-title":"Transl Oncol"},{"key":"32353_CR30","doi-asserted-by":"publisher","first-page":"135","DOI":"10.1038\/gt.2015.105","volume":"23","author":"PY Wang","year":"2016","unstructured":"Wang, P. Y. et al. Neuroblastomas vary widely in their sensitivities to herpes simplex virotherapy unrelated to virus receptors and susceptibility. Gene Ther 23, 135\u2013143, https:\/\/doi.org\/10.1038\/gt.2015.105 (2016).","journal-title":"Gene Ther"},{"key":"32353_CR31","doi-asserted-by":"publisher","first-page":"984","DOI":"10.1038\/gt.2014.72","volume":"21","author":"JD Jackson","year":"2014","unstructured":"Jackson, J. D. et al. Assessment of oncolytic HSV efficacy following increased entry-receptor expression in malignant peripheral nerve sheath tumor cell lines. Gene Ther 21, 984\u2013990, https:\/\/doi.org\/10.1038\/gt.2014.72 (2014).","journal-title":"Gene Ther"},{"key":"32353_CR32","first-page":"59","volume":"50","author":"G Guzman","year":"2006","unstructured":"Guzman, G., Oh, S., Shukla, D., Engelhard, H. H. & Valyi-Nagy, T. Expression of entry receptor nectin-1 of herpes simplex virus 1 and\/or herpes simplex virus 2 in normal and neoplastic human nervous system tissues. Acta Virol 50, 59\u201366 (2006).","journal-title":"Acta Virol"},{"key":"32353_CR33","doi-asserted-by":"publisher","first-page":"588","DOI":"10.1038\/sj.gt.3302462","volume":"12","author":"MA Rueger","year":"2005","unstructured":"Rueger, M. A. et al. Variability in infectivity of primary cell cultures of human brain tumors with HSV-1 amplicon vectors. Gene Ther 12, 588\u2013596, https:\/\/doi.org\/10.1038\/sj.gt.3302462 (2005).","journal-title":"Gene Ther"},{"key":"32353_CR34","doi-asserted-by":"publisher","unstructured":"Cripe, T. P. et al. Pediatric cancer gone viral. Part I: strategies for utilizing oncolytic herpes simplex virus-1 in children. Mol Ther Oncolytics 2, https:\/\/doi.org\/10.1038\/mto.2015.15 (2015).","DOI":"10.1038\/mto.2015.15"},{"key":"32353_CR35","doi-asserted-by":"publisher","first-page":"28","DOI":"10.3389\/fonc.2013.00028","volume":"3","author":"GK Friedman","year":"2013","unstructured":"Friedman, G. K. et al. Pediatric glioma stem cells: biologic strategies for oncolytic HSV virotherapy. Front Oncol 3, 28, https:\/\/doi.org\/10.3389\/fonc.2013.00028 (2013).","journal-title":"Front Oncol"},{"key":"32353_CR36","doi-asserted-by":"publisher","first-page":"227","DOI":"10.1093\/neuonc\/nov123","volume":"18","author":"GK Friedman","year":"2016","unstructured":"Friedman, G. K. et al. Pediatric medulloblastoma xenografts including molecular subgroup 3 and CD133+ and CD15+ cells are sensitive to killing by oncolytic herpes simplex viruses. Neuro Oncol 18, 227\u2013235, https:\/\/doi.org\/10.1093\/neuonc\/nov123 (2016).","journal-title":"Neuro Oncol"},{"key":"32353_CR37","doi-asserted-by":"publisher","first-page":"22","DOI":"10.1016\/j.omto.2017.05.005","volume":"6","author":"AW Studebaker","year":"2017","unstructured":"Studebaker, A. W. et al. Oncolytic Herpes Virus rRp450 Shows Efficacy in Orthotopic Xenograft Group 3\/4 Medulloblastomas and Atypical Teratoid\/Rhabdoid Tumors. Mol Ther Oncolytics 6, 22\u201330, https:\/\/doi.org\/10.1016\/j.omto.2017.05.005 (2017).","journal-title":"Mol Ther Oncolytics"},{"key":"32353_CR38","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.omto.2017.04.002","volume":"5","author":"JV Cockle","year":"2017","unstructured":"Cockle, J. V. et al. Oncolytic Herpes Simplex Virus Inhibits Pediatric Brain Tumor Migration and Invasion. Mol Ther Oncolytics 5, 75\u201386, https:\/\/doi.org\/10.1016\/j.omto.2017.04.002 (2017).","journal-title":"Mol Ther Oncolytics"},{"key":"32353_CR39","doi-asserted-by":"publisher","first-page":"374","DOI":"10.1016\/j.jpeds.2007.04.065","volume":"151","author":"F Xu","year":"2007","unstructured":"Xu, F. et al. Seroprevalence of herpes simplex virus type 1 in children in the United States. J Pediatr 151, 374\u2013377, https:\/\/doi.org\/10.1016\/j.jpeds.2007.04.065 (2007).","journal-title":"J Pediatr"},{"key":"32353_CR40","doi-asserted-by":"publisher","first-page":"14010","DOI":"10.1038\/mto.2014.10","volume":"1","author":"JL Leddon","year":"2015","unstructured":"Leddon, J. L. et al. Oncolytic HSV virotherapy in murine sarcomas differentially triggers an antitumor T-cell response in the absence of virus permissivity. Mol Ther Oncolytics 1, 14010, https:\/\/doi.org\/10.1038\/mto.2014.10 (2015).","journal-title":"Mol Ther Oncolytics"},{"key":"32353_CR41","doi-asserted-by":"publisher","first-page":"4677","DOI":"10.1158\/1078-0432.CCR-07-0776","volume":"13","author":"M Del Vecchio","year":"2007","unstructured":"Del Vecchio, M. et al. Interleukin-12: biological properties and clinical application. Clin Cancer Res 13, 4677\u20134685, https:\/\/doi.org\/10.1158\/1078-0432.CCR-07-0776 (2007).","journal-title":"Clin Cancer Res"},{"key":"32353_CR42","doi-asserted-by":"publisher","first-page":"5304","DOI":"10.1128\/JVI.06998-11","volume":"86","author":"JM Markert","year":"2012","unstructured":"Markert, J. M. et al. Preclinical evaluation of a genetically engineered herpes simplex virus expressing interleukin-12. Journal of virology 86, 5304\u20135313, https:\/\/doi.org\/10.1128\/JVI.06998-11 (2012).","journal-title":"Journal of virology"},{"key":"32353_CR43","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/00005072-198901000-00005","volume":"48","author":"XM He","year":"1989","unstructured":"He, X. M. et al. Phenotypic analysis of four human medulloblastoma cell lines and transplantable xenografts. Journal of neuropathology and experimental neurology 48, 48\u201368 (1989).","journal-title":"Journal of neuropathology and experimental neurology"},{"key":"32353_CR44","first-page":"833","volume":"64","author":"XM He","year":"1991","unstructured":"He, X. M. et al. Differentiation characteristics of newly established medulloblastoma cell lines (D384 Med, D425 Med, and D458 Med) and their transplantable xenografts. Lab Invest 64, 833\u2013843 (1991).","journal-title":"Lab Invest"},{"key":"32353_CR45","doi-asserted-by":"publisher","first-page":"127","DOI":"10.1007\/BF00686634","volume":"35","author":"RH Aaron","year":"1994","unstructured":"Aaron, R. H. et al. Busulfan therapy of central nervous system xenografts in athymic mice. Cancer Chemother Pharmacol 35, 127\u2013131, https:\/\/doi.org\/10.1007\/BF00686634 (1994).","journal-title":"Cancer Chemother Pharmacol"},{"key":"32353_CR46","doi-asserted-by":"publisher","first-page":"1065","DOI":"10.1016\/j.cell.2013.01.036","volume":"152","author":"M Snuderl","year":"2013","unstructured":"Snuderl, M. et al. Targeting placental growth factor\/neuropilin 1 pathway inhibits growth and spread of medulloblastoma. Cell 152, 1065\u20131076, https:\/\/doi.org\/10.1016\/j.cell.2013.01.036 (2013).","journal-title":"Cell"},{"key":"32353_CR47","doi-asserted-by":"publisher","first-page":"49","DOI":"10.1038\/nature11327","volume":"488","author":"PA Northcott","year":"2012","unstructured":"Northcott, P. A. et al. Subgroup-specific structural variation across 1,000 medulloblastoma genomes. Nature 488, 49\u201356, https:\/\/doi.org\/10.1038\/nature11327 (2012).","journal-title":"Nature"},{"key":"32353_CR48","doi-asserted-by":"publisher","first-page":"928","DOI":"10.1002\/pbc.21078","volume":"49","author":"PJ Houghton","year":"2007","unstructured":"Houghton, P. J. et al. The pediatric preclinical testing program: description of models and early testing results. Pediatr Blood Cancer 49, 928\u2013940, https:\/\/doi.org\/10.1002\/pbc.21078 (2007).","journal-title":"Pediatr Blood Cancer"},{"key":"32353_CR49","doi-asserted-by":"publisher","first-page":"213","DOI":"10.1215\/S1152851705000074","volume":"7","author":"EK Hellums","year":"2005","unstructured":"Hellums, E. K. et al. Increased efficacy of an interleukin-12-secreting herpes simplex virus in a syngeneic intracranial murine glioma model. Neuro Oncol 7, 213\u2013224, https:\/\/doi.org\/10.1215\/S1152851705000074 (2005).","journal-title":"Neuro Oncol"},{"key":"32353_CR50","doi-asserted-by":"publisher","first-page":"356","DOI":"10.1038\/gt.2015.5","volume":"22","author":"GK Friedman","year":"2015","unstructured":"Friedman, G. K. et al. Gamma(1)34.5-deleted HSV-1-expressing human cytomegalovirus IRS1 gene kills human glioblastoma cells as efficiently as wild-type HSV-1 in normoxia or hypoxia. Gene Ther 22, 356, https:\/\/doi.org\/10.1038\/gt.2015.5 (2015).","journal-title":"Gene Ther"}],"container-title":["Scientific Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32353-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32353-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32353-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,12,21]],"date-time":"2022-12-21T09:44:45Z","timestamp":1671615885000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41598-018-32353-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2018,9,17]]},"references-count":50,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2018,12]]}},"alternative-id":["32353"],"URL":"https:\/\/doi.org\/10.1038\/s41598-018-32353-x","relation":{},"ISSN":["2045-2322"],"issn-type":[{"value":"2045-2322","type":"electronic"}],"subject":[],"published":{"date-parts":[[2018,9,17]]},"assertion":[{"value":"3 July 2018","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"4 September 2018","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 September 2018","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Drs Markert and Gillespie are founders of and own stock and stock options (<8% interest) in Aettis, Inc., a biotech company that has licensed M032 HSV from The Board of Trustees of the University of Alabama for the University of Alabama at Birmingham. Dr. Gillespie currently serves as one of five unpaid members of the Board of Directors for Aettis, Inc. Dr. Gillespie is a founder of and owns stock and stock options (<10%) in Maji Therapeutics, which is developing other HSVs that are not the subject of the current investigation. Drs Markert and Gillespie were also founders of and owned stock and stock options (<8%) in Catherex Inc., a biotechnology company that had licensed additional intellectual property related to oHSV. Catherex, Inc., was sold to Amgen, Inc., on December 18, 2015, and they no longer participate in any decision making or have any control of any aspect of Catherex or Amgen, although they did receive proceeds from the sale of the company. Dr. Gillespie has served as a paid advisor to the Program Project at the Ohio State University that seeks to find improved methods for application of distinct oHSV to treat localized and metastatic cancers. This is generally, but not specifically, related to the subject matter of this investigation.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing Interests"}}],"article-number":"13930"}}